-
公开(公告)号:US10947207B2
公开(公告)日:2021-03-16
申请号:US16323033
申请日:2017-08-04
IPC分类号: C07D277/42 , C07D263/48 , C07D413/04 , C07D417/04 , C07D487/08 , C07D263/28 , A61K31/4439 , A61K31/421 , A61K31/506 , A61K31/426 , A61P25/00
摘要: There are provided, inter alia, compounds and methods useful for the treatment of neurological conditions, such as neurological disorders and neurodegenerative diseases, including Alzheimer's Disease.
-
公开(公告)号:US11077108B2
公开(公告)日:2021-08-03
申请号:US16330754
申请日:2017-09-06
IPC分类号: C07D239/47 , C07D239/48 , A61K31/506 , A61P25/28 , A61K9/00 , C07D405/12 , C07D239/34 , C07D403/12 , C07D239/52 , A61K31/505 , A61K45/06
摘要: In various embodiments novel allosteric antagonists of the CRFR1 receptor are provided. It discovered that allosteric CRFR1 receptor antagonists are effective to modulate p-Tau levels in Alzheimer's disease (AD) models. In one illustrative embodiment, a compound that is a CRFR1 receptor antagonist is a compound according to the formula or a pharmaceutically acceptable salt, ester, amide, solvate, or prodrug thereof.
-
公开(公告)号:US11243215B2
公开(公告)日:2022-02-08
申请号:US16070249
申请日:2017-01-13
发明人: Varghese John , Jesus Campagna , Tina Bilousova , Patricia R. Spilman , Peter James Heinzelman , Asa Hatami , Mohammad Parvez Alam
IPC分类号: G01N33/543 , G01N33/68 , G01N33/542 , C07D207/46 , G01N33/567 , G01N33/574
摘要: In various embodiments methods are provided for identifying and/or quantifying one or more antigens of interest (biomarkers) on the surface of cell- or tissue-specific exosomes. In an illustrative embodiments the methods comprise: i) incubating a population of exosomes with one or more tissue-specific antibodies that bind an antigen specific to a tissue or cell type of interest that produces exosomes, where the tissue specific antibodies are attached to acceptor bead or magnetic beads so the antibodies bind exosomes displaying the antigen; ii) obtaining a purified population of exosomes bound by the tissue specific antibodies with and/or without photocleavable linker based technology; iii) incubating a test subset of the isolated tissue-specific exosomes with acceptor beads attached to test antibodies that bind an antigen of interest thereby binding exosomes that display the antigen of interest and a control subset with negative control acceptor beads; v) incubating the test subset of isolated exosomes and the control subset of exosomes with a donor-bearing antibody that binds an exosome specific antigen; and vi) detecting a signal produced upon illumination of the control subset and/or the test; and vii) detecting the antigen(s) of interest.
-
4.
公开(公告)号:US20180318216A1
公开(公告)日:2018-11-08
申请号:US15774575
申请日:2016-11-17
发明人: Varghese John , Ichiro Nishimura , Naren Subbiah , Jesus Campagna , Patricia R. Spilman , Mohammad Parvez Alam
IPC分类号: A61K9/127 , A61K9/00 , A61K9/107 , A61K47/64 , A61P35/00 , A61P25/28 , A61K38/17 , C12N15/113 , A61K31/428 , A61K38/50 , A61P25/16 , A61P25/14
CPC分类号: A61K9/127 , A61K9/0014 , A61K9/0019 , A61K9/006 , A61K9/0085 , A61K9/0087 , A61K9/107 , A61K9/1271 , A61K9/19 , A61K9/70 , A61K31/428 , A61K38/1709 , A61K38/50 , A61K47/644 , A61K47/6911 , A61P25/14 , A61P25/16 , A61P25/28 , A61P35/00 , C12N15/113 , C12N2310/141 , C12Y305/01
摘要: In various embodiments deformable nano-scale vehicles (DNV) are provided that are useful for the delivery of therapeutic agents. In certain embodiments the DNVs are capable of transdermal delivery and can additionally cross the blood-brain barrier.
-
5.
公开(公告)号:US20200030457A1
公开(公告)日:2020-01-30
申请号:US16498301
申请日:2018-04-02
发明人: Varghese John , Ichiro Nishimura , Naren Subbiah , Jesus Campagna , Patricia R. Spilman , Mohammad Parvez Alam
摘要: In various embodiments deformable nano-scale vehicles (DNV) are provided that are useful for the delivery of therapeutic agents. In certain embodiments the DNVs are capable of transdermal delivery and can additionally cross the blood-brain barrier.
-
6.
公开(公告)号:US20190307747A1
公开(公告)日:2019-10-10
申请号:US16330754
申请日:2017-09-06
IPC分类号: A61K31/506 , A61K9/00 , A61P25/28
摘要: In various embodiments novel allosteric antagonists of the CRFR1 receptor are provided. It discovered that allosteric CRFR1 receptor antagonists are effective to modulate p-Tau levels in Alzheimer's disease (AD) models.
-
公开(公告)号:US20190292161A1
公开(公告)日:2019-09-26
申请号:US16323033
申请日:2017-08-04
IPC分类号: C07D277/42 , C07D417/04 , C07D263/48 , C07D413/04 , C07D487/08
摘要: There are provided, inter alia, compounds and methods useful for the treatment of neurological conditions, such as neurological disorders and neurodegenerative diseases, including Alzheimer's Disease.
-
8.
公开(公告)号:US20190025330A1
公开(公告)日:2019-01-24
申请号:US16070249
申请日:2017-01-13
发明人: Varghese John , Jesus Campagna , Tina Bilousova , Patricia R. Spilman , Peter James Heinzelman , Asa Hatami , Mohammad Parvez Alam
IPC分类号: G01N33/68 , G01N33/542 , G01N33/543
摘要: In various embodiments methods are provided for identifying and/or quantifying one or more antigens of interest (biomarkers) on the surface of cell- or tissue-specific exosomes. In an illustrative embodiments the methods comprise: i) incubating a population of exosomes with one or more tissue-specific antibodies that bind an antigen specific to a tissue or cell type of interest that produces exosomes, where the tissue specific antibodies are attached to acceptor bead or magnetic beads so the antibodies bind exosomes displaying the antigen; ii) obtaining a purified population of exosomes bound by the tissue specific antibodies with and/or without photo-cleavable linker based technology; iii) incubating a test subset of the isolated tissue-specific exosomes with acceptor beads attached to test antibodies that bind an antigen of interest thereby binding exosomes that display the antigen of interest and a control subset with negative control acceptor beads; v) incubating the test subset of isolated exosomes and the control subset of exosomes with a donor-bearing antibody that binds an exosome specific antigen; and vi) detecting a signal produced upon illumination of the control subset and/or the test; and vii) detecting the antigen(s) of interest.
-
-
-
-
-
-
-